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OBJECTIVE—Diabetic nephropathy is one of the major causes
of renal failure, which is accompanied by the production of
reactive oxygen species (ROS). Nrf2 is the primary transcription
factor that controls the antioxidant response essential for main-
taining cellular redox homeostasis. Here, we report our ﬁndings
demonstrating a protective role of Nrf2 against diabetic
nephropathy.
RESEARCH DESIGN AND METHODS—We explore the pro-
tective role of Nrf2 against diabetic nephropathy using human
kidney biopsy tissues from diabetic nephropathy patients, a
streptozotocin-induced diabetic nephropathy model in Nrf2
/
mice, and cultured human mesangial cells.
RESULTS—The glomeruli of human diabetic nephropathy pa-
tients were under oxidative stress and had elevated Nrf2 levels.
In the animal study, Nrf2 was demonstrated to be crucial in
ameliorating streptozotocin-induced renal damage. This is evi-
dent by Nrf2
/ mice having higher ROS production and suffer-
ing from greater oxidative DNA damage and renal injury
compared with Nrf2
/ mice. Mechanistic studies in both in vivo
and in vitro systems showed that the Nrf2-mediated protection
against diabetic nephropathy is, at least, partially through inhi-
bition of transforming growth factor-1 (TGF-1) and reduction
of extracellular matrix production. In human renal mesangial
cells, high glucose induced ROS production and activated
expression of Nrf2 and its downstream genes. Furthermore,
activation or overexpression of Nrf2 inhibited the promoter
activity of TGF-1 in a dose-dependent manner, whereas
knockdown of Nrf2 by siRNA enhanced TGF-1 transcription
and ﬁbronectin production.
CONCLUSIONS—This work clearly indicates a protective role
of Nrf2 in diabetic nephropathy, suggesting that dietary or
therapeutic activation of Nrf2 could be used as a strategy to
prevent or slow down the progression of diabetic nephropathy.
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A
mong the various types of diabetes complica-
tions, diabetic nephropathy is the most com-
mon renal complication and the leading cause
of end-stage renal disease. The prevalence of
diabetes is high in the U.S., Japan, and most industrialized
European countries (1). As a chronic disease, diabetic
nephropathy is characterized by sequential pathological
changes, including renal hypertrophy and basement mem-
brane thickening in the early stage and extracellular
matrix (ECM) accumulation, glomerulosclerosis, and in-
terstitial ﬁbrosis in the late stage, which eventually results
in the loss of renal function (2,3). Although the pathogen-
esis of diabetic nephropathy is complex and remains
unclear, hyperglycemia is the primary factor that underlies
the initiation of diabetic nephropathy (4). It has been
demonstrated in several in vitro studies that high glucose–
induced renal damage is associated with excessive pro-
duction of reactive oxygen species (ROS) under
hyperglycemic conditions (4–6). In support of this notion,
many renal cell types including mesangial cells, endothe-
lial cells, and tubular epithelial cells were found to pro-
duce high levels of ROS under hyperglycemic conditions
(7–10).
Nrf2 is one of the most important cellular defense
mechanisms to cope with oxidative stress (11,12). It
regulates intracellular antioxidants, phase II detoxifying
enzymes, and many other proteins that detoxify xenobiot-
ics and neutralize ROS to promote cell survival and
maintain cellular redox homeostasis (13). NAD(P)H qui-
none oxidoreductase (NQO1), glutathione S-transferase
(GST), heme oxygenase-1 (HO-1), and -glutamylcysteine
synthetase (GCS) are among the well-studied Nrf2 target
genes that are upregulated through the antioxidant re-
sponse element regulatory element in response to oxida-
tive stress (14,15). The essential role of Nrf2 in combating
oxidative stress induced by a broad spectrum of insults
has been clearly demonstrated by the ﬁndings demonstrat-
ing the increased sensitivity of Nrf2
/ mice to a variety of
insults (14). Recently, the essential role of Nrf2 in protect-
ing against diabetic vascular diseases has emerged. Acti-
vation of Nrf2 by sulforaphane suppressed hyperglycemia-
induced ROS and metabolic dysfunction in human
microvascular endothelial cells (16). Using primary cardi-
omyocytes isolated from Nrf2
/ and Nrf2
/ mice, He
et al. (17) demonstrated that Nrf2 conferred protection
against high glucose–induced oxidative damage. In an-
other study, Yoh et al. (18) reported a beneﬁcial role of
Nrf2 against diabetes using a streptozotocin (STZ)-induced
diabetes model. In their study, higher urinary nitric oxide
metabolites, higher levels of ROS, and a greater degree of
nitrosative DNA damage were detected in STZ-treated
Nrf2
/ mice than in STZ-treated Nrf2
/ mice (18).
During the later stages of diabetic nephropathy, trans-
forming growth factor-1 (TGF-1) overexpression, ECM
deposition, and loss of glomerular architecture deﬁne
glomerulosclerosis (10). Mounting evidence suggests a
role of TGF-1 in the progression of diabetic nephropathy
and glomerulosclerosis by controlling production of many
ECM proteins (19–24). For instance, an anti–TGF-1 anti-
body was reported to be useful in inhibiting glomerulo-
nephritis by blocking ECM production in a mesangial
proliferative glomerulonephritis model (25). Interestingly,
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TGF-1 and Nrf2 pathways. Activation of the TGF-1
pathway was reported to inhibit Nrf2-dependent expres-
sion of the -glutamylcysteine synthetase catalytic sub-
unit, resulting in elevated ROS levels. This in turn further
activated the TGF-1 pathway, leading to excessive pro-
duction of ECM (26). On the other hand, activation of Nrf2
is able to inhibit the function of TGF-1 in a liver ﬁbrosis
mouse model (27). Thus, it is conceivable that activation of
the Nrf2-mediated antioxidant response is beneﬁcial in pre-
venting or slowing down the progression of diabetic ne-
phropathy by reducing ROS and TGF-1–mediated ECM
production. In this article, we show that kidneys from
diabetic nephropathy patients are under oxidative stress.
Consistent with the notion that Nrf2 is beneﬁcial in suppress-
ing the progression of diabetic nephropathy, we observed
that Nrf2
/ mice suffered greater STZ-induced renal dam-
age. Furthermore, a negative role of Nrf2 in controlling the
promoter activity of TGF-1 and ECM production was dem-
onstrated in human mesangial cells (HRMCs).
RESERCH DESIGN AND METHODS
Patients and renal histology. The diabetic nephropathy kidney tissues were
obtained from eight patients with proteinuria that underwent a renal biopsy for
diagnosis of diabetic nephropathy at the Department of Pathology, Shanghai
Medical College, Fudan University, China, in 2007 or 2008. All cases were
diagnosed by two individual pathologists in a double-blind manner. Eight patients
who underwent kidney transplants were biopsied 1 year later to ensure normal
function of their transplanted kidney. These biopsies were then used as the
normal kidney specimens in our study. Permission to use the ﬁxed tissue sections
for research purposes was obtained and approved by the Ethics Committee from
Shanghai Medical College, Fudan University, China, and a written consent form
was obtained from all patients. The parafﬁn sections were stained with hematox-
ylin and eosin (H&E), Congo red, periodic acid Schiff (PAS), and immunoﬂuo-
rescence depositions for diagnosis of diabetic nephropathy.
Animals and treatments. Nrf2
/ mice in C57BL/6 background were gifts
from Dr. Jeff Chan (University of California, Irvine) (28). Nrf2
/ and Nrf2
/
mice (eight mice per group), at 8 weeks of age, were intraperitoneally injected
with STZ (50 mg/kg, pH 4.5) dissolved in sodium citrate or injected with
vehicle (sodium citrate only) for 5 consecutive days. At 16 weeks post-
injection, the mice were killed and the kidneys were isolated.
Blood glucose and urine albumin-to-creatinine ratio measurement.
Blood glucose levels from the tail-vein were measured by the OneTouch Blood
Glucose Monitoring System (LifeScan, Milpitas, CA) at 3, 5, 8, 12, and 16
weeks post-injection. The mice fasted for 4 h before blood glucose measure-
ment. Freshly voided spot urine samples were collected at 1, 8, and 16 weeks
post-injection. Urine albumin and creatinine levels were measured by ELISA
kits (albumin: Bethyl Laboratories, Houston, TX; creatinine: Exocell, Phila-
delphia, PA). The urine albumin-to-creatinine ratio (UACR) was expressed as
the ratio of albumin to creatinine.
Mouse renal histology and detection of oxidative DNA damage. Both
kidneys from each mouse were isolated and cut into two halves. The tissue
was cut into 4-m sections and stained with H&E, PAS, and Masson’s
trichrome. For PAS-stained tissue sections, a ﬁve-grade method was used to
evaluate the sclerosis in glomeruli as described (29). The protocol for
detection of 8-dihydro-2-deoxyguanosine (8-Oxo-dG) requires an additional
step: the deparafﬁnized sections were incubated with proteinase K (10 g/ml)
for 30 min at 37°C and RNase A (100 g/ml) for1ha t37°C and then exposed
to 2 N HCl for 5 min at room temperature, followed by the immunohistochem-
ical analysis. Urinary 8-Oxo-dG was measured using liquid chromatography–
mass spectrometry/mass spectrometry.
Immunohistochemical analysis and antibodies. Kidney tissues were ﬁxed
in 4% buffered paraformaldehyde and embedded in parafﬁn. The deparafﬁnized
sections were boiled in sodium citrate buffer. The primary antibody was used
in a dilution of 1:100 for1ha t37°C and 4°C overnight. For human tissues, an
anti-Nrf2 antibody from Abcam (Cambridge, MA) was used. For mouse
tissues, an anti-Nrf2 polyclonal antibody was used (Santa Cruz Biotechnology,
Santa Cruz, CA). Antibodies against 8-Oxo-7, 8-Oxo-dG (Gaithersburg, MD),
and ﬁbronectin (FN) (Calbiochem, San Diego, CA) were purchased from
commercial sources. NQO1, aldose reductase, GCS, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibodies were all purchased from
Santa Cruz.
qRT-PCR and immunoblot assay. Total RNA from kidney tissues or HRMCs
was extracted using Trizol solution. Equal amounts of RNA (2 g) was
reverse-transcripted into cDNA using the Transcriptor First Strand cDNA
Synthesis Kit (Roche, IN). Taqman probes and primers used in this study are
listed in Table 1. For the bar graph in Fig. 5A, the data represent the average
of eight mice in the same group, each with duplicated samples for qRT-PCR.
The data were expressed as relative mRNA levels normalized to -actin, and
the value from the Nrf2
/ control was set as 1. For the in vitro study with
HRMCs, the experiments were repeated three times with duplicate samples.
For immunoblot analysis, the frozen kidneys were homogenized in lysis buffer
(0.1 mol/l Tris buffer [pH 7.4], 0.1 mmol/l EDTA) in the presence of 1 mmol/l
dithiothreitol, 1 mmol/l phenylmethylsulfonyl ﬂuoride, and a protease inhibi-
tor cocktail (Roche, IN). Protein concentration was determined using the
Bio-Rad DC Protein Assay (Bio-Rad, CA). Protein (300 g) was loaded into
each well and subjected to immunoblot analysis. Each lane in Fig. 5C
contained proteins extracted from the kidney of individual mice.
Cell culture, ROS detection, siRNA transfection, and luciferase re-
porter gene assay. HRMCs were purchased from ScienCell Research Labo-
ratories (Carlsbad, CA) and maintained in RPMI-1640 supplemented with 2%
FBS and mesangial cell growth supplement (ScienCell Research Laborato-
ries). After growth arrested in 0.5% FBS for 24 h, cells were cultured in either
low (1 g/l) or high (5.4 g/l) glucose Dulbecco’s modiﬁed Eagle’s medium
(DMEM) for an additional 24 h before harvest. For ROS measurement, cells
were then incubated for 30 min with dichloroﬂuorescein (5 g/ml) (Sigma, St.
Louis, MO), and the ﬂuorescence intensity was measured by ﬂow cytometry.
Nrf2-siRNA and HiPerfect transfection reagent were purchased from Qiagen
(Valencia, CA), and transfection of Nrf2-siRNA was performed according to
the manufacturer’s instruction. For luciferase reporter gene assay, HRMCs
were transfected with plasmids for TGF-1–promoter-ﬁreﬂy luciferase and
renilla luciferase, along with different amounts of an expression vector for
Nrf2, and then ﬁreﬂy and renilla luciferase activities were measured using a
dual-luciferase reporter gene assay system (Promega, Madison, WI).
Statistical analysis. Results were expressed as means  SD. Statistical tests
were performed using SPSS 10.0. Unpaired Student’s t tests were used to
compare the means of two groups. One-way ANOVA was applied to compare
the means of three or more groups. The Wilcoxon (Gehan) statistical test was
used to analyze survival rate. P  0.05 was considered to be signiﬁcant.
RESULTS
The glomeruli of human diabetic nephropathy pa-
tients were under oxidative stress and underwent
signiﬁcant pathological changes. In total, tissues from
eight normal and eight diabetic nephropathy kidneys were
TABLE 1
Primers and probes used for quantitative RT-PCR
Probe Primer nucleotide sequences
mNrf2 #56 Forward: ttttccattcccgaattacagt
Reverse: aggagatcgatgagtaaaaatggt
mNQ01 #50 Forward: agggttcggtattacgatcc
Reverse: agtacaatcagggctcttctcg
mGST #75 Forward: tctgacccctttccctctg
Reverse: ctgccaggctgtaggaacct
mTGF-1 #56 Forward: tcagacattcgggaagcagt
Reverse: acgccaggaattgttgctat
mFibronectin #50 Forward: cacggaggccaccattact
Reverse: cttcagggcaatgacgtagat
mcollagen IV 	 #56 Forward: ttaaaggactccagggaccac
Reverse: cccactgagcctgtcacac
m-actin #56 Forward: aaggccaaccgtgaaaagat
Reverse: gtggtacgaccagaggcatac
hNrf2 #70 Forward: acacggtccacagctcatc
Reverse: tgtcaatcaaatccatgtcctg
hNQO1 #87 Forward: atgtatgacaaaggacccttcc
Reverse: tcccttgcagagagtacatgg
nHO-1 #25 Forward: aactttcagaagggccaggt
Reverse: ctgggctctccttcttgc
hGST #56 Forward: tccctcatctacaccaactatgag
Reverse: ggtcttgcctccctggtt
hGAPDH #25 Forward: ctgacttcaacagcgacacc
Reverse: tgctgtagccaaattcgttgt
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tics of patients are shown in Table 2. Pathological and
immunohistochemical analyses were performed (Fig. 1).
Compared with normal glomeruli, the glomeruli from
diabetic nephropathy patients showed signiﬁcant morpho-
logical changes (Fig. 1, compare A and B). Two massive
K-W nodules were formed inside the glomerulus of dia-
betic nephropathy patients (Fig. 1B, white arrows). It has
been reported that overproduction of ROS is one of the
major factors mediating tissue damage in diabetes (30).
Thus, Nrf2 is likely activated in the glomeruli of diabetic
nephropathy patients. Next, Nrf2 expression in normal and
diabetic nephropathy glomeruli was measured using im-
munohistochemical analysis. Nrf2 was hardly expressed in
normal glomeruli, whereas it was upregulated in diabetic
nephropathy glomeruli (Fig. 1, compare C and D). In
addition, cells with high expression of Nrf2 in the nucleus
were identiﬁed as mesangial cells (Fig. 1D, arrows).
NQO1, a well-studied Nrf2 target gene, was also activated
in glomeruli of diabetic nephropathy patients (Fig. 1,
compare E and F), indicating the activation of the Nrf2-
mediated antioxidant response. Next, oxidative DNA dam-
age was measured using immunohistochemical analysis
with an anti–8-Oxo-dG antibody. Nuclear staining was
detected in some cells of the glomeruli from diabetic
nephropathy patients, indicting that the diabetic nephrop-
athy kidney is under oxidative damage (Fig. 1, compare G
and H). However, the number of nuclear stained cells was
low in diabetic nephropathy patients because of the mas-
sive glycogen deposition inside the glomeruli (Fig. 1H).
Together, these results demonstrated that the glomeruli of
diabetic nephropathy patients are under severe oxidative
stress and the Nrf2-mediated antioxidant response is
activated.
Nrf2
/ mice suffered greater renal damage induced
by STZ compared with Nrf2
/ mice. During the course
of 16 weeks, some mice in both STZ-treated Nrf2
/ and
Nrf2
/ groups died, but the survival rate between the two
groups did not show any statistical difference (Fig. 2A, P 

0.9477). Blood glucose levels, monitored at 3, 5, 8, 12, and
16 weeks post-injection, were signiﬁcantly increased in
both Nrf2
/ and Nrf2
/ mice after STZ treatment, al-
though no difference in glucose levels was observed
between the two genotype groups (Fig. 2B,* P  0.05).
At 16 weeks post-injection, mice in the STZ-treated
groups had a decrease in their body weight, whereas the
untreated groups gained weight (Fig. 2C,* P  0.05).
Interestingly, Nrf2
/ mice lost more body weight than
Nrf2
/ mice when treated with STZ (Fig. 2C,# P  0.05).
Next, the ratio of kidney to body weight, which indicates
the enlargement of the kidney, was calculated. The ratio
was signiﬁcantly increased in the STZ-treated groups (Fig.
2D,* P  0.05). However, there was no difference in the
ratio of kidney to body weight between the two genotypes,
even in the treated groups, which may be due to the
greater decrease in body weight of the Nrf2
/ mice (Fig.
2D). As an index of renal function, UACR was measured at
0, 8, and 16 weeks after STZ injection. STZ markedly
enhanced UACR at both 8 and 16 weeks post-injection
(Fig. 2E,* P  0.05). Although no difference was observed
between Nrf2
/ and Nrf2
/ mice at 8 weeks post-
injection, the Nrf2
/ mice showed a signiﬁcantly higher
UACR than Nrf2
/ mice at 16 weeks post-injection (Fig.
2E,# P  0.05). All these results indicate that Nrf2
/ mice
suffered greater renal damage, implicating the essential
role of Nrf2 in protecting against STZ-induced diabetic
nephropathy.
Higher levels of oxidative stress and oxidative dam-
age occurred in the glomeruli of Nrf2
/ mice than in
Nrf2
/ mice in response to STZ. Next, STZ-induced
oxidative stress were measured by Nrf2 activation and
oxidative DNA damage. Nrf2
/ mice did not have any
detectable levels of Nrf2 in their glomeruli, conﬁrming the
complete deletion of Nrf2 (Fig. 3A, c and d). Nrf2 expres-
sion was greatly enhanced in the glomeruli of the STZ-
treated Nrf2
/ group and Nrf2 nuclear staining was
observed (Fig. 3A, compare a and b, and the insert of b).
Activation of Nrf2 was conﬁrmed by upregulation of NQO1
in response to STZ treatment in Nrf2
/ mice, but not in
Nrf2
/ mice (Fig. 3A, i–l). To test the role of Nrf2 in
ameliorating oxidative damage under the diabetic ne-
phropathy condition, oxidative DNA damage was com-
pared in the glomeruli of Nrf2
/ and Nrf2
/ mice using
immunohistochemical analysis with an anti–8-Oxo-dG an-
tibody. The results reveal that the STZ-treated Nrf2
/
mice had a greater degree of oxidative damage than the
STZ-treated Nrf2
/ mice (Fig. 3A, compare f and h).
Intriguingly, Nrf2
/ mice displayed higher levels of oxi-
dative damage even in the untreated condition (Fig. 3A,
compare e and g), indicating that the basal level of Nrf2 is
essential in protecting against DNA damage induced by
intrinsic sources of ROS. Consistent with these results,
higher levels of basal and STZ-induced oxidative DNA
damage in Nrf2
/ mice were conﬁrmed by measuring the
urinary level of 8-Oxo-dG (Fig. 3B). These results clearly
demonstrate that Nrf2
/ mice had higher production of
ROS in response to STZ challenge and were more vulner-
able to ROS-induced damage due to loss of Nrf2.
Nrf2
/ mice had more severe glomerular injury than
Nrf2
/ mice. Kidneys were isolated and processed for
pathological analysis using H&E, PAS, and Masson’s
trichrome staining. Glomerular lesions were detected in
both Nrf2
/ and Nrf2
/ mice after STZ injection in
H&E-stained tissue sections (Fig. 4A, compare a and b,
and c and d; K-W nodules are labeled with arrows in b and
d). Next, glycogen deposition was measured by PAS
staining (Fig. 4A, e–h). The severity of glomerulosclerosis
was scored using a semiquantitative method, and the
result is shown in Fig. 4B. STZ signiﬁcantly induced
glomerulosclerosis in both genotype groups (Fig. 4A,
compare e and f, and g and h; Fig. 4B,* P  0.05).
Moreover, Nrf2
/ mice showed a higher score than
TABLE 2
Selected clinical characteristics of patients in the study group
Control
Diabetic
nephropathy patients
with proteinuria
n 88
Sex (M/F) 6/2 7/1
Age 59  84 7  5
Duration of diabetes N 13  8
A1C (%) NA 8.8  0.9
Systolic blood pressure
(mmHg) NA 127  14
Diastolic blood pressure
(mmHg) NA 76  12
BMI (kg/m
2) NA 26  4.8
Albumin excretion rate
(g/min) NA 664.2 (233.0–769.1)
Data are means  SD. N, no diabetic nephropathy. NA, not available.
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/ mice in response to STZ treatment (Fig. 4A,
compare f and h; Fig. 4B, #P  0.05). In addition, K-W
nodules were also observed in PAS-stained tissues in the
STZ-treated groups (Fig. 4A, compare e and f, and g and h,
black arrows in f and h). ECM deposition in glomeruli is a
hallmark of many renal diseases including diabetic ne-
phropathy (31,32), Therefore, collagens and FN, the major
components of ECM, were measured using Masson’s
trichrome staining method and immunohistochemical
analysis with an anti-FN antibody, respectively. Collagen
deposition was observed inside the glomeruli of the STZ-
treated Nrf2
/ mice, but not in STZ-treated Nrf2
/ mice
(Fig. 4A, compare j and l). Slight collagen deposition in the
untreated Nrf2
/ mice was also observed (Fig. 4A, k). In
response to STZ treatment, expression of FN was in-
creased in both genotype groups (Fig. 3A, compare m and
A B
C D
E F
G H
FIG. 1. Signiﬁcant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Renal biopsy
samples were ﬁxed and cut into 2-m sections; the sections were subjected to H&E staining (A and B) and immunohistochemical analysis with
anti-Nrf2 (C and D), anti-NQO1 (E and F), and anti–8-Oxo-dG (G and H) antibodies. The images shown are representative of eight normal kidney
tissue patients (A, C, E, and G) and eight kidney tissues from diabetic nephropathy patients (B, D, F, and H). Magniﬁcation is 400. White and
black arrows (B and D) indicate K-W nodules and the Nrf2-positive nuclei, respectively. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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damage in untreated Nrf2
/ mice (Fig. 3A, g), the basal
level of FN expression in Nrf2
/ was also higher than that
in Nrf2
/ mice (Fig. 4A, compare m and o). Collectively,
these results demonstrate that Nrf2 is essential in protect-
ing against both basal and STZ-induced glomerular injury.
Nrf2
/ mice had higher TGF-1 transcription and
FN expression. Next, the molecular mechanism by which
Nrf2 protects against STZ-induced glomerular injury was
explored. First, activation of the Nrf2 pathway by STZ-
induced ROS was tested. Data shown in Fig. 5A represent
the average reading of eight mice in each group. As
expected, there was no Nrf2 mRNA detected in Nrf2
/
mice (Fig. 5A, Nrf2 panel #P  0.05). In addition, STZ
treatment did not induce Nrf2 mRNA expression in
Nrf2
/ mice (Fig. 5A, Nrf2 panel), which is consistent
with the previous ﬁndings that upregulation of Nrf2 is
primarily regulated at the level of Nrf2 protein stability.
However, the downstream genes of Nrf2, NQO1, and GST
were transcriptionally activated in response to STZ in
Nrf2
/ mice and only slightly in Nrf2
/ mice (Fig. 5,
NQO1 and GST panels,* P  0.05), indicating the activa-
tion of the Nrf2-mediated antioxidant response. Intrigu-
ingly, although both basal and STZ-induced levels of NQO1
in Nrf2
/ mice were lower than that in Nrf2
/ mice, the
basal level of GST was similar between these two geno-
type groups (Fig. 5A, NQO1 panel,# P  0.05, and GST
panel).
Next, mRNA expression of TGF-1, FN, and collagen IV
were measured. As shown in Fig. 5B, the basal level of
TGF-1 in Nrf2
/ mice is higher than Nrf2
/ mice (Fig.
5B, TGF-1 panel,# P  0.05). STZ treatment induced
transcription of TGF-1 in both Nrf2
/ and Nrf2
/ mice,
and the highest transcription was observed in the STZ-
treated Nrf2
/ mice (Fig. 5B, TGF-1 panel,* P  0.05,
#P  0.05). In agreement with the notion that TGF-1
positively regulates expression of FN, the mRNA expres-
sion pattern of FN is similar to that of TGF-1 (Fig. 5B, FN
panel,* P  0.05, #P  0.05), demonstrating that FN was
overexpressed, especially in the STZ-treated Nrf2
/ mice.
FIG. 2. Nrf2
/ mice suffered greater renal damage by STZ
compared with Nrf2
/ mice. During the course of 16 weeks
after STZ injection, the survival rate of mice was recorded and
plotted (A). Tail-vein blood glucose levels were monitored at
3, 5, 8, 12, and 16 weeks post-injection (B). Mice were killed at
16 weeks post-injection. Whole-body and kidney weight were
measured. The body weight in four different groups at 16
weeks post-injection is shown in C. The ratio of kidney to body
weight was calculated (D). UACR was also measured at 0, 8,
and 16 weeks post-injection (E). *P < 0.05 untreated vs.
STZ-treated; #P < 0.05 Nrf2
/ vs. Nrf2
/. Data are expressed
as means  SD (n  8).
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mRNA expression in Nrf2
/ mice was higher, compared
with Nrf2
/ mice (Fig. 5B, collagen IV panel,# P  0.05),
there was no difference in collagen IV mRNA expression
between the control and STZ-treated groups. It is likely
that the observed collagen deposition in the glomeruli of
the STZ-treated Nrf2
/ mice in the Masson’s trichrome
stained tissues (Fig. 4, l) came from other types of
collagen, rather than collagen IV. In another set of exper-
iments, NQO1 and FN were chosen as representative Nrf2
and TGF-1 downstream genes, respectively, and their
protein levels were measured by immunoblot analysis.
NQO1 was induced by STZ treatment in Nrf2
/ mice,
while there was no detectable level of NQO1 in Nrf2
/
mice (Fig. 5C, NQO1 panel). Quantiﬁcation data showed
nearly fourfold induction of NQO1 in response to STZ in
Nrf2
/ mice (Fig. 5C, lower left panel,* P  0.05). The
protein level of FN was induced more than three- to
FIG. 3. Higher levels of oxidative stress and oxidative damage occurred in the glomeruli of Nrf2
/ mice than in Nrf2
/ mice in response to STZ.
At 16 weeks post-injection, Nrf2
/ and Nrf2
/ mice were killed and kidneys were isolated. Kidney tissue sections from each mouse were used
for immunohistochemical analysis with anti-Nrf2 (A, a–d), anti–8-Oxo-dG (A, e–h), and anti-NQO1 (A, i–L) antibodies. Nuclear staining of Nrf2
is shown in the insert (Fig. A, b). Each image is a representative of eight kidney tissue sections from eight mice in each group. Urinary 8-Oxo-dG
was detected by liquid chromatography–mass spectrometry (B). *P < 0.05 vs. Nrf2
/ mice; #P < 0.05. (A high-quality color representation of this
ﬁgure is available in the online issue.)
FIG. 4. Nrf2
/ mice had more severe glomerular injury than Nrf2
/ mice. Kidney tissue sections were subject to H&E (Fig. A, a–d), PAS (A, e–h),
and trichrome staining (A, i–L), as well as immunohistochemical analysis with an anti-FN antibody (A, m–p). Each image is a representative of
eight kidney tissue sections from eight mice in each group. PAS-stained tissues were used for semiquantitative scoring as described in the
RESEARCH DESIGN AND METHODS. Glomerulosclerosis index for four different groups is shown in B. In total, 30 glomeruli were scored for each mouse.
*P < 0.05 untreated vs. STZ-treated; #P < 0.05 Nrf2
/ vs. Nrf2
/. Data are expressed as means  SD (n  8). (A high-quality color
representation of this ﬁgure is available in the online issue.)
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/ mice had higher TGF-1 transcription and FN expression. The mRNA level of Nrf2, NQO1, and GST (A) and TGF-1, FN, and
collagen IV (B) was measured by qRT-PCR. The data presented are relative mRNA level normalized to -actin mRNA level, and the value from
the untreated Nrf2
/ group was set as 1. *P < 0.05 untreated vs. STZ-treated; #P < 0.05 Nrf2
/ vs. Nrf2
/. Data are expressed as means  SD
(n  8). The protein level of FN, NQO1, and GAPDH was measured by immunoblot analysis (C, upper panel). Each lane contained total proteins
from the kidney of different individual mice. The band intensity was calculated and normalized to GAPDH (C, lower panel). The value from the
untreated Nrf2
/ group was set as 1. *P < 0.05 untreated vs. STZ-treated; #P < 0.05 Nrf2
/ vs. Nrf2
/. Data are expressed as means  SD
(n  3).
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/ and Nrf2
/
mice (Fig. 5C, FN panel, and lower right panel,* P  0.05).
Furthermore, Nrf2
/ mice had both higher basal and
STZ-induced levels of FN than Nrf2
/ mice, with the
highest FN expression detected in the STZ-treated Nrf2
/
mice (Fig. 5C, FN panel, and lower right panel,# P  0.05).
Taken together, these data demonstrate that STZ is able to
activate the Nrf2-mediated antioxidant response, which in
turn negatively regulates TGF-1–mediated ECM produc-
tion, especially FN.
Nrf2 was activated by high glucose–induced ROS
production in HRMCs. To further conﬁrm that the
activation of Nrf2 by STZ in vivo is due to high glucose–
induced ROS production, in vitro experiments were
carried out. Because mesangial cells play a crucial role
in the initiation and progression of many renal diseases,
including diabetic nephropathy (31,33), HRMCs were
used for this in vitro study. An enhanced nuclear protein
level of Nrf2 was detected in cells growing under high
glucose medium compared with low glucose medium
(Fig. 6A,* P  0.05). Consistent with this result, high
glucose induced the mRNA level of NQO1, HO-1, and
GST, without affecting Nrf2 mRNA levels (Fig. 6B,* P 
0.05), indicating the activation of the Nrf2 pathway. This
in vitro study recapitulates the observed Nrf2 activation
in STZ-treated Nrf2
/ mice and in human renal tissues
from a diabetic nephropathy patient. It is conceivable
that high glucose induced Nrf2 activity through ROS
production. Thus, ROS levels were measured. Indeed,
the cells growing in high glucose medium had substan-
tially higher levels of ROS (Fig. 6C,* P  0.05). To
further conﬁrm the notion that Nrf2 activation by high
glucose is through generation of ROS, N-acetylcysteine
(NAC), a ROS scavenger, was included in the medium.
As shown in Fig. 6D, NAC inhibited the activation of
high glucose–induced Nrf2 and NQO1 (Fig. 6D,* P 
0.05, #P  0.05). Collectively, these results indicate that
hyperglycemia is able to activate the Nrf2 pathway
through generation of ROS.
FIG. 6. Nrf2 was activated by high glucose–induced ROS production in HRMCs. Before exposure to low-glucose (LG) (1 g/l) or high-glucose (HG)
(5.4 g/l) DMEM, cells were starved for 24 h with low-glucose DMEM containing 0.5% FBS. Cells were then incubated in low- and high-glucose
DMEM for an additional 24 h. Nuclear and cytosolic fractions were extracted and subjected to immunoblot analysis using anti-Nrf2, anti-lamin
A, and anti-tubulin antibodies (A, left panel). The intensity of the bands was calculated and quantiﬁed (A, right panel). Total mRNA was
extracted and used for qRT-PCR for measurement of the mRNA level of Nrf2, HO-1, NQO1, or GST (B). ROS level was also measured in these cells
growing in low- or high-glucose medium by dichloroﬂuorescein (DCF)/ﬂow cytometry analysis described in RESEARCH DESIGN AND METHODS (C).
HRMCs were incubated with NAC (50 mol/l) for 24 h. Total cell lysates were subjected to immunoblot analysis using anti-Nrf2, anti-NQO1, and
anti-GAPDH antibodies (D, left panel). The intensity of the bands was quantiﬁed (D, right panel).
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To conﬁrm the negative effects of Nrf2 on TGF-1, as
observed in the in vivo study shown in Fig. 5B, regulation
of the TGF-1 promoter activity by Nrf2 was studied using
luciferase reporter gene analysis. Overexpression of Nrf2
inhibited the promoter activity of TGF-1 in a dose-
dependent manner (Fig. 7A, upper panel,* P  0.05).
Overexpression of Nrf2 was conﬁrmed by immunoblot
analysis with an anti-HA antibody (Fig. 7A, lower anti-HA
panel). Consistent with the result obtained from overex-
pressed Nrf2, induction of endogenous Nrf2 by tert-butyl-
hydroquinone inhibited the promoter activity of TGF-1i n
a dose-dependent manner (Fig. 7B, upper panel,* P  0.05,
and lower anti-Nrf2 panel). Consistent with the Nrf2-
mediated negative regulation of the TGF-1 promoter,
Nrf2 also negatively regulated the protein level of FN, a
TGF-1–downstream gene (Fig. 7A and B, FN panel). In
addition, changes in TGF-1 mRNA in response to reduced
expression of Nrf2 by Nrf2-siRNA were measured in cells
growing in low- and high-glucose medium. As expected,
cells growing in high glucose medium had a higher level of
TGF-1 expression (Fig. 7C,* P  0.05). Knockdown of
FIG. 7. Nrf2 negatively regulated TGF-1 and FN in HRMCs. HRMCs
growing were transfected with plasmids for TGF-1–promoter-ﬁre-
ﬂy luciferase and renilla luciferase (internal control), along with
different amounts of an expression vector for Nrf2. At 48 h post-
transfection, both ﬁreﬂy and renilla luciferase activities were mea-
sured (A, upper panel). An aliquot of cell lysates was used for
immunoblot analysis (A, lower panel). HRMCs were transfected
with plasmids for TGF-1–promoter-ﬁreﬂy luciferase and renilla
luciferase. Cells were then treated with tert-butylhydroquinone
(tBHQ) for 16 h before the measurement of luciferase at 48 h
post-transfection (B, upper panel). An aliquot of cell lysates was
used for immunoblot analysis (B, lower panel). HRMCs were trans-
fected with control- or Nrf2-siRNA. Then 24 h later, cells were
starved before incubation with low- or high-glucose medium for an
additional 24 h. Total mRNAs were extracted, and qRT-PCR was
performed to measure the mRNA level of TGF-1( C). Another
parallel set of cells was collected in lysis buffer for immunoblot
analysis with antibodies against Nrf2, aldose reductase (AR), GCS,
NQO1, FN, and GAPDH (D, upper panel). The intensity of the bands
was calculated and quantiﬁed (D, lower panel). All the experiments
were repeated three times and data represent means  SD.
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both conditions (Fig. 7C,# P  0.05), again demonstrating
the negative effect of Nrf2 on TGF-1 expression. Next,
another parallel set of samples was used for immunoblot
analysis. High glucose induced Nrf2, aldose reductase,
GCS, and NQO1, as well as FN (Fig. 7D, compare lane 1
and 3,* P  0.05). Nrf2-siRNA reduced the protein levels of
Nrf2, aldose reductase, GCS, and NQO1, while it en-
hanced FN in both low- and high-glucose medium (Fig. 7D,
compare lane 1 and 2, and lane 3 and 4,# P  0.05).
DISCUSSION
In the present study, a protective role of Nrf2 against
diabetic nephropathy is clearly demonstrated through
multiple approaches. First, human kidney tissues were
used, and the results indicate that the glomeruli of human
diabetic nephropathy patients were under oxidative stress,
as demonstrated by oxidative DNA damage and activation
of the Nrf2-mediated pathway. Second, a STZ-induced
diabetes mouse model in Nrf2
/ mice was used to
demonstrate the importance of Nrf2 in alleviating hyper-
glycemia-induced renal damage. Nrf2
/ mice had higher
ROS production and suffered from greater oxidative DNA
damage. This was recapitulated in HRMCs using media
containing high glucose, showing an increase in ROS,
which was attenuated when the cells were treated with the
antioxidant supplement NAC (Fig. 6D). In addition,
Nrf2
/ mice manifested severe proteinuria and glomeru-
losclerosis and thus suffered a greater degree of renal
injury than Nrf2
/ mice. Consistent with our ﬁndings that
Nrf2 plays an important role in alleviating renal damage
caused by ROS production, Liu et al. (34) demonstrated
that renal function, histology, vascular permeability, and
survival were signiﬁcantly worse in Nrf2
/ mice under
ischemic conditions, which was blocked by NAC or gluta-
thione treatment. To further verify that Nrf2 protects
against ROS, a future in vivo study should be conducted
using NAC or glutathione to conﬁrm that antioxidants
reduce ROS-induced damage in Nrf2
/ mice.
Finally, the possibility that Nrf2 negatively regulates
TGF-1 and its downstream events, such as ECM produc-
tion, was explored both in mice and in cultured mesangial
cells. Strikingly, the basal mRNA level of TGF-1, FN, and
collagen IV in Nrf2
/ mice was increased signiﬁcantly
compared with Nrf2
/ mice, indicating the negative effect
of Nrf2 on the TGF-1 pathway. This notion was further
conﬁrmed by the higher basal and induced protein levels
of FN in Nrf2
/ mice. In HRMCs, high glucose induced
ROS production and activated expression of Nrf2 and its
downstream genes. Furthermore, the activation or overex-
pression of Nrf2 inhibited the promoter activity of TGF-1
in a dose-dependent manner, whereas knockdown of Nrf2
by siRNA enhanced TGF-1 transcription and FN produc-
tion. This work clearly establishes a critical role of Nrf2 in
protecting against diabetic nephropathy.
Because Nrf2 and NQO1 were upregulated exclusively
in the kidneys of all eight diabetic nephropathy patients, it
is most likely that the Nrf2-mediated antioxidant response
pathway is intact in diabetic nephropathy patients. Then
the question is, why did the Nrf2-mediated antioxidant
response fail to protect these patients with diabetic ne-
phropathy? We believe that activation of Nrf2 before
disease development or during the early stage of diabetic
nephropathy is the key for intervention to prevent ROS-
induced damage and diabetic nephropathy progression. At
the late stage of diabetic nephropathy, the Nrf2-mediated
protective mechanism is saturated by excessive ROS,
resulting in renal damage. Elucidation of the Nrf2-medi-
ated defense system as a protective mechanism against
diabetic nephropathy will help us to develop novel thera-
peutic interventions targeting Nrf2 to prevent or slow the
progression of diabetic nephropathy.
Based on the ﬁndings from this study, we propose a model
by which Nrf2 confers protection again diabetic nephropa-
thy. Under hyperglycemic conditions, glomerular cells pro-
duce excessive amounts of ROS, which elicits many re-
sponses having both beneﬁcial and harmful outcomes in
terms of renal function. Upregulation of TGF-1 by ROS will
lead to excessive production of ECM, resulting in glomerular
sclerosis/ﬁbrosis, and ultimately loss of renal function. In
addition, ROS may directly damage macromolecules, such as
DNA, proteins, and lipids, which results in renal cell death
and loss of function. To prevent ROS-induced damage, cells
have evolved the Nrf2-mediated defense mechanism to cope
with deleterious conditions. Activation of Nrf2 by stress
improves renal function through at least the following two
mechanisms: ﬁrst is to neutralize ROS and thus reduce
ROS-mediated damage, and second is to downregulate
TGF-1 and therefore alleviate ECM production. Currently,
the detailed mechanism by which Nrf2 downregulates the
transcription of TGF-1 is unclear. Whether Nrf2 negatively
regulates TGF-1 by direct binding to the promoter region of
TGF-1, or by reducing ROS and ROS-induced upregulation
of TGF-1, is currently under investigation.
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